GlycOmega-Plus (Perna canaliculus extract)

GlycOmega-Plus is a standardized extract of Perna canaliculus (green-lipped mussel) concentrated for omega-3 fatty acids, glycosaminoglycans, and furanyl fatty acids that inhibit both COX and 5-LOX inflammatory enzymes. Its primary mechanism involves dual cyclooxygenase-lipoxygenase pathway suppression, reducing prostaglandin and leukotriene synthesis in synovial tissue to relieve osteoarthritis pain and stiffness.

Origin & History

GlycOmega-Plus is a branded extract derived from Perna canaliculus (green-lipped mussel), a bivalve mollusk native to New Zealand. The extract is obtained through processing of the mussel tissue to concentrate bioactive compounds including lipids, proteins, and polysaccharides.

Historical & Cultural Context

The research dossier does not contain information regarding traditional or historical use of Perna canaliculus in traditional medicine systems. Modern commercial use appears to have emerged from New Zealand's aquaculture industry.

Health Benefits

• Reduces osteoarthritis pain - A 12-week RCT (n=93) showed significant improvements in K-VAS pain scores (moderate evidence quality)
• Improves joint function - Clinical trial demonstrated significant improvements in K-WOMAC functional scores compared to placebo (moderate evidence quality)
• Suppresses inflammatory markers - In vitro studies showed significant reduction in COX-2 and iNOS expression (preliminary evidence)
• Modulates immune response - Laboratory research demonstrated downregulation of NF-κB signaling and TLR4 expression (preliminary evidence)
• Superior safety profile - Clinical trial reported only 4% adverse events versus 16% in placebo group (moderate evidence quality)

How It Works

GlycOmega-Plus exerts anti-inflammatory effects through dual inhibition of cyclooxygenase (COX-1/COX-2) and 5-lipoxygenase (5-LOX) enzymes, reducing downstream synthesis of pro-inflammatory prostaglandins (PGE2) and leukotrienes (LTB4) in synovial tissue. The furanyl fatty acids and omega-3 polyunsaturated fatty acids (EPA, DHA) present in the extract compete with arachidonic acid for enzyme binding sites, attenuating the arachidonic acid cascade. Additionally, glycosaminoglycans such as chondroitin sulfate contribute to cartilage matrix support by stimulating proteoglycan synthesis in chondrocytes and inhibiting matrix metalloproteinases (MMPs) that degrade articular cartilage.

Scientific Research

A multicenter, randomized, double-blind, placebo-controlled trial (n=93) demonstrated statistically significant improvements in pain and functional outcomes over 12 weeks with green-lipped mussel extract. Preclinical studies in dogs showed efficacy comparable to meloxicam, a standard NSAID, at 6 weeks. A Phase 1 safety trial (ACTRN12611000517976) was registered for knee osteoarthritis, though detailed results were not available.

Clinical Summary

A 12-week randomized, placebo-controlled trial (n=93) demonstrated statistically significant improvements in K-VAS (Knee Visual Analog Scale) pain scores in participants with knee osteoarthritis receiving GlycOmega-Plus, with evidence rated as moderate quality. The same trial reported significant gains in K-WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) functional subscores compared to placebo, indicating improvements in physical function and stiffness. Broader Perna canaliculus literature, including a Cochrane-reviewed meta-analysis of green-lipped mussel preparations, supports analgesic and functional benefits over 8–12 weeks, though effect sizes are modest and studies vary in extract standardization. Evidence is considered moderate overall, with larger multicenter trials needed to confirm optimal dosing and long-term efficacy.

Nutritional Profile

GlycOmega-Plus is a proprietary extract derived from Perna canaliculus (New Zealand green-lipped mussel). Key bioactive compounds include: Glycosaminoglycans (GAGs) - primarily chondroitin sulfate and dermatan sulfate, estimated at 20-30% of dry extract weight; Omega-3 polyunsaturated fatty acids (PUFAs) - including EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid), with a unique additional PUFA eicosatetraenoic acid (ETA, 20:4n-3) present at approximately 2-5% of total fatty acid content, contributing to COX-2 inhibitory activity; Total lipid content approximately 10-15% of extract; Protein content approximately 50-60% of dry weight, including collagen precursor peptides; Minerals: naturally occurring zinc (~15-25 mg/100g), selenium (~0.1-0.3 mg/100g), copper, and manganese in trace amounts; Glycoproteins and mucopolysaccharides contributing to joint matrix support. Bioavailability notes: The lipid-stabilized extract format in GlycOmega-Plus is designed to preserve heat-sensitive omega-3 fractions and GAG integrity; co-presence of lipids may enhance absorption of fat-soluble bioactives; ETA bioavailability is considered superior in whole-extract form compared to isolated fractions. Typical serving concentrations in clinical studies ranged from 300-600 mg of extract per day.

Preparation & Dosage

The clinical trials used proprietary formulations administered once daily for 12 weeks, but specific dosage amounts for GlycOmega-Plus were not detailed in the available research. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Glucosamine sulfate, Chondroitin sulfate, MSM, Turmeric extract, Boswellia serrata

Safety & Interactions

GlycOmega-Plus is generally well tolerated; the most commonly reported adverse effects are mild gastrointestinal symptoms including nausea, loose stools, and bloating, particularly when taken on an empty stomach. Individuals with shellfish allergies should avoid this supplement, as Perna canaliculus is a bivalve mollusk and allergic reactions including urticaria and anaphylaxis have been reported. Due to the omega-3 content and antiplatelet properties, caution is advised in patients taking anticoagulants such as warfarin or antiplatelet drugs like aspirin and clopidogrel, as additive bleeding risk is theoretically possible. Safety data in pregnant or breastfeeding women is insufficient, and use during pregnancy is not recommended without medical supervision.